Indications of Capmatinib

It is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (mNSCLC) whose tumors have been identified as having MET exon 14 skipping mutation by an FDA-approved companion diagnostic test (it has been granted orphan drug designation for this indication by the FDA). Information on FDA-approved companion diagnostic tests for the detection of MET mutations in non-small cell lung cancer can be found on the FDA website. The current indication is based on objective response rate and duration of response; continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory studies.

from FDA,2023.03